Lv591
900 积分 2026-07-17 加入
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
1个月前
已完结
Overview of contemporary guidelines for management of acute type A aortic dissection
1个月前
已完结
Cefepime–Taniborbactam in Complicated Urinary Tract Infection
1个月前
已完结
Lowering the Acquisition of Multidrug-Resistant Organisms (MDROs) With Pulsed-xenon (LAMP) Study: A Cluster-Randomized, Controlled, Double-Blinded, Interventional Crossover Trial
1个月前
已关闭
Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: A randomized controlled trial
1个月前
已完结
Changes in the prevalence of pathogens causing hospital-acquired bacterial pneumonia and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity-score-matched study
2个月前
已完结
Effectiveness Comparison Between Ceftazidime-Avibactam and Carbapenem-Based Regimens in Nosocomial Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
2个月前
已完结
A phase III randomized controlled non-inferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) versus piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
2个月前
已完结
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
2个月前
已完结
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
2个月前
已完结
皖公网安备34019202002308
